Business Description
Lixte Biotechnology Holdings Inc
NAICS : 325412
SIC : 2834
ISIN : US5393193017
Description
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.93 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 2.9 | |||||
| 3-Year EPS without NRI Growth Rate | 2.8 | |||||
| 3-Year FCF Growth Rate | -5.9 | |||||
| 3-Year Book Growth Rate | -43.5 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 14-Day RSI | 52.83 | |||||
| 12-1 Month Momentum % | -37.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.72 | |||||
| Quick Ratio | 13.72 | |||||
| Cash Ratio | 13.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -22 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -121.95 | |||||
| ROA % | -112.89 | |||||
| ROIC % | -5357.89 | |||||
| ROCE % | -121.55 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 14.82 | |||||
| Price-to-Tangible-Book | 14.82 | |||||
| EV-to-EBIT | -1.31 | |||||
| EV-to-EBITDA | -1.31 | |||||
| EV-to-FCF | -1.54 | |||||
| Price-to-Net-Current-Asset-Value | 14.82 | |||||
| Price-to-Net-Cash | 1.89 | |||||
| Earnings Yield (Greenblatt) % | -76.34 | |||||
| FCF Yield % | -58.53 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lixte Biotechnology Holdings Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.129 | ||
| Beta | 0 | ||
| Volatility % | 36.19 | ||
| 14-Day RSI | 52.83 | ||
| 14-Day ATR (€) | 0.000007 | ||
| 20-Day SMA (€) | 6.1 | ||
| 12-1 Month Momentum % | -37.44 | ||
| 52-Week Range (€) | 4.6 - 10.8 | ||
| Shares Outstanding (Mil) | 2.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lixte Biotechnology Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lixte Biotechnology Holdings Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lixte Biotechnology Holdings Inc Frequently Asked Questions
What is Lixte Biotechnology Holdings Inc(FRA:8640)'s stock price today?
The current price of FRA:8640 is €6.10. The 52 week high of FRA:8640 is €10.80 and 52 week low is €4.60.
When is next earnings date of Lixte Biotechnology Holdings Inc(FRA:8640)?
The next earnings date of Lixte Biotechnology Holdings Inc(FRA:8640) is 2024-05-10 Est..
Does Lixte Biotechnology Holdings Inc(FRA:8640) pay dividends? If so, how much?
Lixte Biotechnology Holdings Inc(FRA:8640) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers